Studying engraftment syndrome after stem cell transplants
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at people who have had a donor stem cell transplant and then develop a condition called engraftment syndrome, where the new immune cells cause symptoms like fever, rash, or swelling. The goal is to learn more about the different types of this condition and how it affects recovery, so doctors can better predict and manage outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor (allogeneic transplant)
- You developed engraftment syndrome after the transplant (symptoms like fever, rash, or fluid retention that are not from infection)
- You have enough medical records and lab results (like blood tests) to help doctors understand your symptoms
- You are willing to be followed at the hospital to track your recovery and any complications
- You can give written permission to be in the study (or have a legal representative do so)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in your blood and in tissues affected by chronic graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant. By analyzing samples, researchers hope to better understand this condition and improve future treatments.
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
Hear when a new Engraftment Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.